期刊文献+

乙型肝炎免疫球蛋白联合泰来肽对感染HBV孕妇血清和初乳HBV-DNA含量的影响 被引量:3

The Effect of HBIG Combined with Tailaitai on Levels of HBV-DNA of Colostrum and HBV-Infected Pregnancy Serum
暂未订购
导出
摘要 目的研究乙型肝炎免疫球蛋白(HBIG)和泰来肽(TLT)对感染HBV孕妇血清和初乳HBV-DNA含量的影响。方法选择感染HBV的孕妇(HBsAg、HBeAg、HBV-DNA阳性)162例,分为:治疗Ⅰ组50例,于妊娠20周起肌肉注射HBIG200IU,1次/月,至分娩为止;治疗Ⅱ组40例,在治疗Ⅰ组肌注HBIG的基础上自妊娠28周起肌注TLT2ml,1次/d,至分娩为止;对照组72例,自然观察。分别采集孕妇治疗前、后血清和初乳,检测HBV-DNA含量。结果治疗前3组孕妇血清HBV-DNA含量间差别无显著性意义(P>0.05);治疗后3组孕妇血清和初乳HBV-DNA含量间差别均有显著性意义(P<0.05),而治疗后治疗Ⅰ、Ⅱ组孕妇血清和初乳HBV-DNA含量间差异均无显著性意义(P>0.05)。结论HBIG联合TLT与单独使用HBIG对孕妇血清和初乳中HBV-DNA的含量无差别。 Objective To study the effect of HBIG combined with Tailaitai(TLT)on levels of HBV-DNA of colostrum and HBV-infected pregnancy serum.Methods 72 gravidas were selected as a control group,who were observed naturally,162 were divided into two groups:Group Ⅰ(50 gravidas),who were given intramuscular(IM)injections of HBIG(200 IU,once a month)from the 20th week to delivery time,Group Ⅱ(40 gravidas),who were given additional IM of TLT(once daily,from the 28th week to delivery time)besides HBIG.We examined the levels of HBV-DNA of serum and colostrum,which were collected respectively before and after the treatment.Results There was no significant difference in levels of serum HBV-DNA among the three groups before treatment(P〉0.05),Significant difference was observed in levels of HBV-DNA of serum and colostrum among the three groups after treatment(P〈0.05),There was no significant difference in levels of HBV-DNA of serum and colostrum between Group Ⅰ and Group Ⅱ after treatment(P〉0.05).Conclusion The treatment with HBIG combined with TLT has the same effect as that with only HBIG on HBV-DNA levels of pregnancy serum and colostrum.
出处 《中国全科医学》 CAS CSCD 2007年第22期1879-1880,共2页 Chinese General Practice
关键词 免疫法 被动 泰来肽 肝炎 乙型 Immunization,passive Tailaitai Hepatitis B
  • 相关文献

参考文献5

二级参考文献43

共引文献16

同被引文献25

  • 1卞继峰,于修平.人乳头瘤病毒致癌机制的研究进展[J].中国病毒学,2004,19(5):531-534. 被引量:11
  • 2李从铸,翟玉霞.宫颈癌年轻化及其治疗模式的临床研究[J].癌变·畸变·突变,2005,17(1):36-38. 被引量:21
  • 3Parkin DM,Bray F,Ferlay J,et al.Estimating the world cancer burden:Globocan 2000.Int J cancer,2001,94(2):153-156.
  • 4Steben M,Duarte-Franco E.Human papillomavirus infection:epidemiology and pathophysiology.Gynecol Oncol,2007,107 (2 Suppl 1):S2-5.
  • 5zur Hausen H,Meinhof W,Scheiber W,et al.Attempts to detect virus-secific DNA in human tumors.I.Nucleic acid hybridizationswith complementary RNA of human wart virus.Int J Cancer,1974,13(5):650-656.
  • 6Cuschieri K,Wentzensen N.Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.Cancer Epidemiol Biomarkers Prev,2008,17 (10):2536-2545.
  • 7Hwang TS,Jeong JK,Park M,et al.Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray.Gynecol Onco1,2003,90(1):51-56.
  • 8Cox JT.Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.Obstet Gynecol Surv,2006,61 (6):S15-25.
  • 9Slebos RJ,Lee MH,Plunkett BS,et al.p53-dependent Gl arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.Proc Natl Acad Sci USA,1994,91(12):5320-5324.
  • 10Brandsma JL,Shlyankevich M,Zelterman D,et al.Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1,E2,E6 and E7 DNA vaccine.Vaccine,2007,25 (33):6158-6163.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部